Genotoxicity studies of ubidecarenone (coenzyme Q10) manufactured by bacteria fermentation

Abstract

-Ubidecarenone (coenzyme Q10) has been widely used as a complementary therapy in heart failure and as a dietary supplement for over two decades. Ubidecarenone is manufactured by organic synthesis, yeast (non-Saccharomyces cerevisiae) fermentation, or bacteria fermentation. There are many reports on the safety of ubidecarenone. However, genotoxicity of ubidecarenone manufactured by bacteria fermentation has not been reported. We carried out genotoxicity evaluation of ubidecarenone manufactured by bacteria fermentation through the bacterial reverse mutation test (Ames test) and in vitro chromosome aberration test in compliance with the Japanese guidelines on genotoxicity testing of phartesting chemicals. The results indicate neither increase of revertant colonies nor chromosome aberration, suggesting that the ubidecarenone manufactured by bacteria fermentation has no genotoxic activities under the condition of this study.

Coenzyme Q10 supplementation in non-alcoholic fatty liver disease: an overview

“…CoQ10 is well tolerated in healthy adults at an intake of 900 mg/day, and in rats at a dose of up to 1200 mg/Kg/day. In addition, Yamaguchi et al (2009) reported that CoQ10 had no genotoxic activity. CoQ10 is not recommended for pregnant or lactating women, in whom the effects of CoQ10 have not been extensively studied.…”